PENUMBRA DEADLINE ALERT: Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Penumbra To Contact Him Directly To Discuss Their Options

NEW YORK, Jan. 23, 2021 (GLOBE NEWSWIRE) — Faruqi & Faruqi, LLP, a leading minority and certified woman-owned national securities law firm, is investigating potential claims against Penumbra, Inc. (“Penumbra” or the “Company”) (NYSE:PEN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you suffered losses exceeding $100,000 investing in Penumbra stock or options between August 3, 2020 and December 15, 2020 and would like to discuss your legal rights, click here: www.faruqilaw.com/PEN or call Faruqi & Faruqi partner James Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).

FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
877.247.4292
212.983.9330
jwilson@faruqilaw.com

There is no cost or obligation to you.

As detailed below, the lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose: (1) that the Jet 7 Xtra Flex had known design defects that made it unsafe for its normal use; (2) that Penumbra did not adequately address the risk of the Jet 7 Xtra Flex causing serious injury and deaths, which had in fact already occurred; (3) that the Jet 7 Xtra Flex was likely to be recalled due to its safety issues; and (4) as a result, Penumbra’s public statements as set forth above were materially false and misleading at all relevant times.

First, on September 14, 2020, the Foundation for Financial Journalism (the “FFJ”), an independent non-profit news outlet, published an article raising serious questions about the Jet 7 Xtra Flex’s safety profile. The FFJ noted that since being introduced in mid-2019, there were twelve deaths listed in a Food and Drug Administration (“FDA”) database that occurred after a surgeon injected an iodine contrast dye into the Jet 7 Xtra Flex. The FFJ article described how Penumbra’s warnings against using the product with contrast dye and non-Penumbra products did little to address the Jet 7 Xtra Flex’s safety issues.

In response, Penumbra’s stock price fell by nearly 3%, from $199.43 per share on September 11, 2020 to $193.66 per share on September 14, 2020, a decline of $5.77 per share.

Then, on November 23, 2020, an article was published in the Journal of NeuroInterventional Surgery presenting the cases of three patients who suffered as a result of Jet 7 Xtra Flex device malfunctions, including two fatalities. Although the journal article was not widely publicized on November 23 aside from a Twitter post just before market close from an account with a small following, over the next two days the article was more widely disseminated, particularly after it was shared by multiple reputed short sellers with hundreds of thousands of followers, including Marc Cohodes and Muddy Waters.

As this report became more widely circulated, it caused Penumbra stock to fall from $254.71 on November 23, 2020 to $224.12 on November 25, 2020, a decline of about 12%.

Then, on December 8, 2020, before the market opened, QCM issued another report reiterating its prior assertions and disclosing additional facts about the Jet 7 Xtra Flex’s safety issues. Among other things, QCM’s second report questioned the validity and independence of the scientific research supporting the Jet 7 Xtra Flex’s safety, and accused the Company of using a fake author to publish studies regarding the purported safety and efficacy of its products.

In response, Penumbra’s stock price fell by 9%, from $224.02 per share on December 7, 2020 to $204.07 per share on December 8, 2020, a decline of $19.95 per share.

Finally, on December 15, 2020, after the market closed, the Company issued a press release announcing that it was issuing an “urgent” recall of the Jet 7 Xtra Flex because the catheter “may become susceptible to distal tip damage during use” which could lead to injury or death. On a conference call held the same day, the Company’s CEO acknowledged that the product’s design “ma[de] the catheter susceptible to failure in certain scenarios” and that the Company’s “steps to ensure the safe use of the product . . . were not able to fully address the risks.”

In response, Penumbra’s stock price fell by 7%, from $188.82 per share on December 15, 2020 to $174.98 per share on December 16, 2020, a decline of $13.84 per share.

The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.  

Faruqi & Faruqi, LLP also encourages anyone with information regarding Penumbra’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.